Combining therapies to improve treatment for ovarian cancer
Mechanisms of Selective Therapeutic Synergy of PARP-inhibition and CTLA4 Blockade Engaged by Interferon-gamma in the Ovarian Tumor Microenvironment
This study is looking at how pairing two types of cancer treatments—PARP inhibitors and immune checkpoint blockers—might work better together to help women with ovarian cancer fight their disease and live longer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of New Mexico Health Scis Ctr NIH-funded |
| Lab location | 1 site (Albuquerque, United States) |
| Project ID | NIH-11044207 on NIH RePORTER |
What this research studies
This research investigates how combining PARP inhibitors with immune checkpoint blockade can enhance treatment responses in ovarian cancer. The approach focuses on understanding the interactions between these therapies and the tumor microenvironment, particularly how they can promote immune responses against cancer cells. By studying these mechanisms, the research aims to identify ways to improve patient outcomes and potentially extend survival rates for women with ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer, particularly those whose tumors have not responded well to existing therapies.
Not a fit: Patients with ovarian cancer who have already achieved durable responses to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results when combining PARP inhibitors with immune therapies in other cancer types, suggesting potential for success in ovarian cancer as well.
Where this research is happening
Albuquerque, United States
- University of New Mexico Health Scis Ctr — Albuquerque, United States (Active)
Researchers
- Principal investigator: Adams, Sarah Foster — University of New Mexico Health Scis Ctr
- Study coordinator: Adams, Sarah Foster
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.